Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that data from the Phase 2 trial of its PSMA imaging agent candidate, 1404, will be presented at the upcoming Radiological Society of North America Annual Meeting, taking place in Chicago from November 30 – December 5, 2014. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) belongs to Healthcare sector. Its net profit margin is 16.70% and weekly performance is 4.28%. On last trading … Continue reading Hot Stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Peregrine Semiconductor Corporation (NASDAQ:PSMI), Alcoa Inc. (NYSE:AA), Silvercrest Mines Inc. (NYSEMKT:SVLC), Southern First Bancshares, Inc. (NASDAQ:SFST)